MedlinePlus a602015 CAS ID 192725-17-0 | Routes ofadministration Oral Molar mass 628.81 g/mol | |
 | ||
AHFS/Drugs.com International Drug Names Pregnancycategory US: C (Risk not ruled out) Legal status UK: POM (Prescription only)US: ℞-only | ||
Lopinavir and ritonavir treat hiv infections overview
Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra (high-income countries) and Aluvia (low-income countries). It was first approved by the FDA on 15 September 2000.
Contents
- Lopinavir and ritonavir treat hiv infections overview
- Lopinavir and ritonavir medication overview
- Pharmacology
- Side effects
- Research
- References
Lopinavir and ritonavir medication overview
Pharmacology
Lopinavir is highly bound to plasma proteins (98–99%).
Reports are contradictory regarding lopinavir penetration into the cerebrospinal fluid (CSF). Anecdotal reports state that lopinavir cannot be detected in the CSF; however, a study of paired CSF-plasma samples from 26 patients receiving lopinavir/ritonavir found lopinavir CSF levels above the IC50 in 77% of samples.
Side effects
Side effects, interactions, and contraindications have only been evaluated in the drug combination lopinavir/ritonavir.
Research
A 2014 study indicates that lopinavir is effective against the human papilloma virus (HPV). The study used the equivalent of one tablet twice a day applied topically to the cervices of women with high-grade and low-grade precancerous conditions. After three months of treatment, 82.6% of the women who had high-grade disease had normal cervical conditions, confirmed by smears and biopsies.